Linezolid Serum Levels: the number that decides whether you keep the drug
Why is linezolid the drug where TDM changes management most often?
In MDR/XDR regimens linezolid is a Group A agent — you do not want to lose it. But its toxicity is exposure- and duration-dependent: myelosuppression (anaemia, thrombocytopenia, leucopenia) typically appears within weeks, while peripheral and optic neuropathy accumulate over months and may not fully reverse. Efficacy, meanwhile, tracks with sustained exposure above the MIC.
So the clinical question is never "linezolid: yes or no". It is "how much linezolid can this patient absorb, and is the current dose sitting inside the window or outside it?" Without a level, a cytopenia usually ends with the drug being stopped. With a level, a dose reduction may keep the drug in the regimen.
| Situation | What a level adds |
|---|---|
| New cytopenia on linezolid | Distinguishes exposure-driven marrow suppression from another cause; supports a dose reduction rather than discontinuation. |
| Numbness, tingling, visual change | Neuropathy is the toxicity that may not reverse — evidence of high exposure argues for acting before it becomes permanent. |
| Slow response on a BPaL/BPaLM regimen | Confirms whether the patient is actually achieving the exposure the regimen assumes. |
| Renal impairment / dialysis | Clearance changes; empiric dosing is unreliable. |
← TB therapeutic drug monitoring — service overview
FAQ
- What specimen and timing does a linezolid level need?
- Serum, drawn at defined times relative to an observed dose. Because both efficacy and toxicity are exposure-driven, the draw time is what makes the number interpretable - call the lab before the first patient and we will send the collection protocol.
- Can a level let us keep linezolid instead of stopping it?
- That is the most common reason clinicians order it. A cytopenia in a patient with a high measured exposure supports a dose reduction; stopping a Group A drug outright weakens the regimen. The decision remains the treating physician's.
- Do you measure the other MDR drugs too?
- Yes - cycloserine, ethionamide, moxifloxacin, rifabutin and pretomanid, alongside the four first-line drugs. All by LC-MS/MS in serum.
References
- ATS / CDC / IDSA — Treatment of Drug-Resistant Tuberculosis.
- WHO — Consolidated guidelines on drug-resistant TB treatment (BPaL/BPaLM).
- CDC — TB clinical care.
Reach us — privately
No name needed to ask a question. Text is the fastest way to reach us.
Or send your details below — we will reply by text or email during open hours.